Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Sep 4;83(7):899–905. doi: 10.1054/bjoc.2000.1372

Use of thymidine analogues to indicate vascular perfusion in tumours

A C Begg 1, I Hofland 1, I Van Der Pavert 2, B Van Der Schueren 3, K Haustermans 1,3
PMCID: PMC2374690  PMID: 10970692

Abstract

Temporary reduction in blood-flow within tumour blood vessels can reduce oxygen supply leading to transient perfusion-limited hypoxia. Consequent selection of cells with mutations and reduced radiosensitivity can lead to disease progression and treatment-resistance. In the present study, we investigated whether heterogeneity of labelling after thymidine analogue administration is related to perfusion variations, and if so, could it be quantified and used as a perfusion indicator. Perfusion in murine RIF1 tumours was reduced by hydralazine or increased by nicotinamide and the mice subsequently injected with IdUrd. Tumours were halved for analysis by both flow cytometry and immunohistochemistry. Tumour sections were stained for vasculature and IdUrd. Each blood vessel was scored for the density of IdUrd-labelled cells surrounding it, using a semi-quantitative scoring system. Flow cytometry showed that the IdUrd labelling index and intensity decreased by approximately 50% after hydralazine. In tumour sections of control animals, 2.9% of vessels showed no IdUrd label. In contrast, after hydralazine almost 50% of vessels had no surrounding IdUrd labelling, whereas after nicotinamide there were fewer vessels with low labelling and a higher median score. In conclusion, changes of tumour perfusion by pharmacological agents is reflected in changes in tumour-cell labelling by the thymidine analogue IdUrd, suggesting that IdUrd labelling could be used to indicate perfusion in individual vessels in human tumours. © 2000 Cancer Research Campaign

Keywords: tumour perfusion, IdUrd, hypoxia, image analysis, flow cytometry

Full Text

The Full Text of this article is available as a PDF (862.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Begg A. C., Haustermans K., Hart A. A., Dische S., Saunders M., Zackrisson B., Gustaffson H., Coucke P., Paschoud N., Hoyer M. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol. 1999 Jan;50(1):13–23. doi: 10.1016/s0167-8140(98)00147-9. [DOI] [PubMed] [Google Scholar]
  2. Begg A. C., Moonen L., Hofland I., Dessing M., Bartelink H. Human tumour cell kinetics using a monoclonal antibody against iododeoxyuridine: intratumour sampling variations. Radiother Oncol. 1988 Apr;11(4):337–347. doi: 10.1016/0167-8140(88)90205-8. [DOI] [PubMed] [Google Scholar]
  3. Begg A. C. The clinical status of Tpot as a predictor? Or why no tempest in the Tpot! Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1539–1541. doi: 10.1016/0360-3016(95)00261-V. [DOI] [PubMed] [Google Scholar]
  4. Bernsen H. J., Rijken P. F., Oostendorp T., van der Kogel A. J. Vascularity and perfusion of human gliomas xenografted in the athymic nude mouse. Br J Cancer. 1995 Apr;71(4):721–726. doi: 10.1038/bjc.1995.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bollinger A. Microlymphatics of human skin. Int J Microcirc Clin Exp. 1993 Feb;12(1):1–15. [PubMed] [Google Scholar]
  6. Brown J. M. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol. 1979 Aug;52(620):650–656. doi: 10.1259/0007-1285-52-620-650. [DOI] [PubMed] [Google Scholar]
  7. Chaplin D. J., Durand R. E., Olive P. L. Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1279–1282. doi: 10.1016/0360-3016(86)90153-7. [DOI] [PubMed] [Google Scholar]
  8. Chaplin D. J., Olive P. L., Durand R. E. Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res. 1987 Jan 15;47(2):597–601. [PubMed] [Google Scholar]
  9. Dewhirst M. W. Concepts of oxygen transport at the microcirculatory level. Semin Radiat Oncol. 1998 Jul;8(3):143–150. doi: 10.1016/s1053-4296(98)80040-4. [DOI] [PubMed] [Google Scholar]
  10. Durand R. E. Oxygen enhancement ratio in V79 spheroids. Radiat Res. 1983 Nov;96(2):322–334. [PubMed] [Google Scholar]
  11. Honess D. J., Bleehen N. M. Effects of the radiosensitising agent nicotinamide on relative tissue perfusion and kidney function in C3H mice. Radiother Oncol. 1993 May;27(2):140–148. doi: 10.1016/0167-8140(93)90134-t. [DOI] [PubMed] [Google Scholar]
  12. Honess D. J., Bleehen N. M. Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined. Br J Cancer. 1995 Jun;71(6):1175–1180. doi: 10.1038/bjc.1995.229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Horsman M. R., Chaplin D. J., Brown J. M. Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. Radiat Res. 1987 Mar;109(3):479–489. [PubMed] [Google Scholar]
  14. Huber M., Franzeck U. K., Bollinger A. Permeability of superficial lymphatic capillaries in human skin to FITC-labelled dextrans 40 000 and 150 000. Int J Microcirc Clin Exp. 1984;3(1):59–69. [PubMed] [Google Scholar]
  15. Kimura H., Braun R. D., Ong E. T., Hsu R., Secomb T. W., Papahadjopoulos D., Hong K., Dewhirst M. W. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 1996 Dec 1;56(23):5522–5528. [PubMed] [Google Scholar]
  16. Kotelnikov V., Cass L., Coon J. S., Spaulding D., Preisler H. D. Accuracy of histone H3 messenger RNA in situ hybridization for the assessment of cell proliferation in human tissues. Clin Cancer Res. 1997 May;3(5):669–673. [PubMed] [Google Scholar]
  17. Reinhold H. S., van den Berg-Blok A. Vascularization of experimental tumours. Ciba Found Symp. 1983;100:100–119. doi: 10.1002/9780470720813.ch7. [DOI] [PubMed] [Google Scholar]
  18. Spiro I. J., Rice G. C., Durand R. E., Stickler R., Ling C. C. Cell killing, radiosensitization and cell cycle redistribution induced by chronic hypoxia. Int J Radiat Oncol Biol Phys. 1984 Aug;10(8):1275–1280. doi: 10.1016/0360-3016(84)90332-8. [DOI] [PubMed] [Google Scholar]
  19. Sutherland R. M., Franko A. J. On the nature of the radiobiologically hypoxic fraction in tumors. Int J Radiat Oncol Biol Phys. 1980 Jan;6(1):117–120. doi: 10.1016/0360-3016(80)90215-1. [DOI] [PubMed] [Google Scholar]
  20. THOMLINSON R. H., GRAY L. H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955 Dec;9(4):539–549. doi: 10.1038/bjc.1955.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Trotter M. J., Acker B. D., Chaplin D. J. Histological evidence for nonperfused vasculature in a murine tumor following hydralazine administration. Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):785–789. doi: 10.1016/0360-3016(89)90067-9. [DOI] [PubMed] [Google Scholar]
  22. Trotter M. J., Chaplin D. J., Durand R. E., Olive P. L. The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):931–934. doi: 10.1016/0360-3016(89)90889-4. [DOI] [PubMed] [Google Scholar]
  23. Twentyman P. R., Brown J. M., Gray J. W., Franko A. J., Scoles M. A., Kallman R. F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst. 1980 Mar;64(3):595–604. [PubMed] [Google Scholar]
  24. van Geel I. P., Oppelaar H., Rijken P. F., Bernsen H. J., Hagemeier N. E., van der Kogel A. J., Hodgkiss R. J., Stewart F. A. Vascular perfusion and hypoxic areas in RIF-1 tumours after photodynamic therapy. Br J Cancer. 1996 Feb;73(3):288–293. doi: 10.1038/bjc.1996.51. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES